These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 20231858)

  • 1. Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians.
    Gebeyehu E; Engidawork E; Bijnsdorp A; Aminy A; Diczfalusy U; Aklillu E
    Pharmacogenomics J; 2011 Apr; 11(2):130-7. PubMed ID: 20231858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians.
    Diczfalusy U; Miura J; Roh HK; Mirghani RA; Sayi J; Larsson H; Bodin KG; Allqvist A; Jande M; Kim JW; Aklillu E; Gustafsson LL; Bertilsson L
    Pharmacogenet Genomics; 2008 Mar; 18(3):201-8. PubMed ID: 18300941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnancy Increases CYP3A Enzymes Activity as Measured by the 4β-Hydroxycholesterol/Cholesterol Ratio.
    Mlugu EM; Minzi OM; Kamuhabwa AAR; Diczfalusy U; Aklillu E
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of effects of indoxyl sulfate and parathyroid hormone on CYP3A activity considering the influence of CYP3A5 gene polymorphisms.
    Oda A; Suzuki Y; Yoshijima C; Sato H; Tanaka R; Ono H; Tatsuta R; Ando T; Shin T; Itoh H; Ohno K
    Br J Clin Pharmacol; 2023 Dec; 89(12):3648-3658. PubMed ID: 37522799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans.
    Diczfalusy U; Nylén H; Elander P; Bertilsson L
    Br J Clin Pharmacol; 2011 Feb; 71(2):183-9. PubMed ID: 21219398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of CYP3A5 genotype on tolvaptan pharmacokinetics and their relationships with endogenous markers of CYP3A activity and serum sodium level in heart failure patients.
    Hoshikawa K; Naito T; Akutsu S; Saotome M; Maekawa Y; Kawakami J
    Basic Clin Pharmacol Toxicol; 2020 Apr; 126(4):353-363. PubMed ID: 31652395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of plasma concentration of 4β-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients.
    Suzuki Y; Itoh H; Fujioka T; Sato F; Kawasaki K; Sato Y; Sato Y; Ohno K; Mimata H; Kishino S
    Drug Metab Dispos; 2014 Jan; 42(1):105-10. PubMed ID: 24135442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between the plasma fentanyl and serum 4β-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer pain.
    Ishida T; Naito T; Sato H; Kawakami J
    Drug Metab Pharmacokinet; 2016 Jun; 31(3):242-8. PubMed ID: 27236640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys.
    Li K; Zhao S; Zhang L; Wu X; Shu P; Wang Y; Feng H; Gu Z; Han Hsu H
    Drug Metab Dispos; 2014 May; 42(5):839-43. PubMed ID: 24595680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors involved in phenoconversion of CYP3A using 4β-hydroxycholesterol in stable kidney transplant recipients.
    Suzuki Y; Muraya N; Fujioka T; Sato F; Tanaka R; Matsumoto K; Sato Y; Ohno K; Mimata H; Kishino S; Itoh H
    Pharmacol Rep; 2019 Apr; 71(2):276-281. PubMed ID: 30826567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the usefulness of plasma 4β-hydroxycholesterol concentration normalized by 4α-hydroxycholesterol for accurate CYP3A phenotyping.
    Oda A; Suzuki Y; Sato H; Koyama T; Nakatochi M; Momozawa Y; Tanaka R; Ono H; Tatsuta R; Ando T; Shin T; Wakai K; Matsuo K; Itoh H; Ohno K
    Clin Transl Sci; 2024 Mar; 17(3):e13768. PubMed ID: 38465776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.
    Vanhove T; de Jonge H; de Loor H; Annaert P; Diczfalusy U; Kuypers DR
    Br J Clin Pharmacol; 2016 Dec; 82(6):1539-1549. PubMed ID: 27501475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the CYP3A5 genotype on omeprazole sulfoxidation in CYP2C19 PMs.
    Sugimoto K; Uno T; Tateishi T
    Eur J Clin Pharmacol; 2008 Jun; 64(6):583-7. PubMed ID: 18214455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of 4β-Hydroxycholesterol and 25-Hydroxycholesterol as Endogenous Biomarkers of CYP3A4: Study with CYP3A-Humanized Mice.
    Nitta SI; Hashimoto M; Kazuki Y; Takehara S; Suzuki H; Oshimura M; Akita H; Chiba K; Kobayashi K
    AAPS J; 2018 Apr; 20(3):61. PubMed ID: 29858698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4β-hydroxycholesterol.
    Nylén H; Sergel S; Forsberg L; Lindemalm S; Bertilsson L; Wide K; Diczfalusy U
    Eur J Clin Pharmacol; 2011 Jul; 67(7):715-22. PubMed ID: 21246351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP3A activity based on plasma 4β-hydroxycholesterol during the early postpartum period has an effect on the plasma disposition of amlodipine.
    Naito T; Kubono N; Ishida T; Deguchi S; Sugihara M; Itoh H; Kanayama N; Kawakami J
    Drug Metab Pharmacokinet; 2015 Dec; 30(6):419-24. PubMed ID: 26654672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of induced CYP3A activity in pregnant women using 4β-hydroxycholesterol: Cholesterol ratio as an appropriate metabolic marker.
    Kim AH; Kim B; Rhee SJ; Lee Y; Park JS; Lee SM; Kim SM; Lee S; Yu KS; Jang IJ; Cho JY
    Drug Metab Pharmacokinet; 2018 Jun; 33(3):173-178. PubMed ID: 29759884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels.
    Josephson F; Bertilsson L; Böttiger Y; Flamholc L; Gisslén M; Ormaasen V; Sönnerborg A; Diczfalusy U
    Eur J Clin Pharmacol; 2008 Aug; 64(8):775-81. PubMed ID: 18458892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of 4β-Hydroxycholesterol Plasma Concentrations as an Endogenous Biomarker of CYP3A Activity: Clinical Validation in Individuals With Type 2 Diabetes.
    Gravel S; Chiasson JL; Gaudette F; Turgeon J; Michaud V
    Clin Pharmacol Ther; 2019 Oct; 106(4):831-840. PubMed ID: 31002385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4β-Hydroxycholesterol as an Endogenous Biomarker for CYP3A Activity: Literature Review and Critical Evaluation.
    Penzak SR; Rojas-Fernandez C
    J Clin Pharmacol; 2019 May; 59(5):611-624. PubMed ID: 30748026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.